Business
AVITA Medical Reports First Quarter 2026 Financial Results
VALENCIA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights and Recent Business Updates Total revenue of approximately $19.3 million, up 4% year-over-year and approximately 10% sequentially, driven by contributions from Cohea
About this update from Avita Medical, Inc.
[{"type":"image","alt":"AVITA Medical","displaySize":"","headline":null,"caption":"AVITA Medical","className":"","disableSlideshowImg":false,"size":{"original":{"width":96,"height":115,"url":"https://media.zenfs.com/en/globenewswire.com/dfd8c445a107185ef69e74538692859e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Qqfn8nNdgV10AMCqRfyvsg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTEzMg--/https://media.zenfs.com/en/globenewswire.com/dfd8c445a107185ef69e74538692859e","width":96,"height":115},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/Qqfn8nNdgV10AMCqRfyvsg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTEzMg--/https://media.zenfs.com/en/globenewswire.com/dfd8c445a107185ef69e74538692859e","width":96,"height":115}},"lazy":false},{"type":"text","content":"VALENCIA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the first quarter ended March 31, 2026.","length":294,"tagName":"p"},{"type":"text","content":"First Quarter 2026 Financial Highlights and Recent Business Updates","length":67,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue of approximately $19.3 million, up 4% year-over-year and approximately 10% sequentially, driven by contributions from Cohealyx® and improved RECELL® utilization as reimbursement dynamics normalize","length":210,"tagName":"p"}]},{"val":[{"type":"text","content":"Appointment of Cary Vance as President and Chief Executive Officer following a comprehensive search process led by a special committee of the Board of Directors, reflecting confidence in the Company’s strategic direction and operational progress; Jan Stern Reed appointed as independent Chair of the Board","length":305,"tagName":"p"}]},{"val":[{"type":"text","content":"Gross profit margin of 81.7%, reflecting impact of product mix and certain inventory adjustments","length":96,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating expenses decreased 11% year-over-year to $24.5 million, reflecting a lower and more disciplined cost base established in 2025","length":135,"tagName":"p"}]},{"val":[{"type":"text","content":"Net cash use of approximately $9.9 million in the quarter, reflecting one-time items and the timing of revenue and collection...